Molecular and pharmacological aspects of antiestrogen resistance

Journal of Steroid Biochemistry and Molecular Biology

Volumn 76, Issue 1-5, 2001, Pages 71-84

  Clarke, Robert ^a   Skaar, Todd C ^a   Bouker, Kerrie B ^a   Davis, Natalie ^a   Richard Lee, Y ^a   Welch, James N ^a   Leonessa, Fabio ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antiestrogen resistance; Molecular aspects; Pharmacological aspects

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTIESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; RALOXIFENE; STEROID; STEROID HORMONE; TAMOXIFEN CITRATE; TAMOXIFEN DERIVATIVE; TOREMIFENE;

BREAST CARCINOMA; CANCER CELL; CONFERENCE PAPER; CROSS RESISTANCE; DRUG MECHANISM; DRUG RESPONSE; DRUG SPECIFICITY; GENE CONTROL; GENE EXPRESSION; GENOTYPE; HORMONAL THERAPY; HOT FLUSH; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR GROWTH;

CELL DIVISION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; GROWTH SUBSTANCES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, HORMONE-DEPENDENT; OXIDATIVE STRESS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 0034992614     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00193-X     Document Type: Article

References (131)

1. A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
4. Prevention of breast cancer with Tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women
5. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial
6. Tamoxifen for early breast cancer: An overview of the randomized trials
7. Treatment of metastatic disease: Hormonal therapy and chemotherapy
8. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial
9. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer
10. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer
11. Response to a specific antioestrogen (ICI 182, 780) in tamoxifen-resistant breast cancer
12. Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
13. Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover
14. Differential ligand activation of estrogen receptors ER-alpha and ER-beta at AP1 sites
15. Alterations in mammary gland development following neonatal exposure to estradiol, transforming growth factor alpha, and estrogen receptor antagonist ICI 182, 780
16. A pure antiestrogen, ICI 182, 780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro
17. Effects of Raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
18. The effect of raloxifene on risk of breast cancer in postmenopausal women; results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
19. Adverse events reported by postmenopausal women in controlled trials with raloxifene
20. Molecular basis of agonism and antagonism in the oestrogen receptor
21. Identification of an estrogen response element activated by metabolites of 17β-estradiol and Raloxifene
22. Identification of selective estrogen receptor modulators by their gene expression fingerprints
23. Cellular and molecular pharmacology of antiestrogen action and resistance
24. Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer
25. Acquired estrogen independence and antiestrogen resistance in breast cancer: Estrogen receptor-driven phenotypes?
26. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
27. Heterogeneity of progesterone receptor content and remodelling by tamoxifen characterize subpopulations of cultured human breast cancer cells: Analysis by quantitative dual parameter flow cytometry
28. Estrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers
29. Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast tumors
30. Characterization of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and stability of the resistant phenotype
31. Estrogen receptor mutagenesis and hormone resistance
32. Estrogen receptor variants
33. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER
34. MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen
35. Analysis of single-, double- and multiple-exon deletion transcripts of estrogen receptor in breast cancer cell lines and tumors by a novel approach
36. Hormonal aspects of breast cancer: Growth factors, drugs and stromal interactions
37. Growth factors in breast cancer
38. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
39. Clinical significance of tamoxifen withdrawal response
40. Differential effects of estrogen and antiestrogen on in vitro clonogenic growth of human breast cancers in soft agar
41. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice
42. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice
43. Analysis of tyrosine kinase mRNAs including four FGF receptors expressed in the MCF-7 breast cancer cells
44. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells
45. A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens
46. Reversal of tamoxifen resistance of human breast carcinomas in vivo with neutralizing anti-transforming growth factor (TGF)-β antibodies involves paracrine mechanisms
47. Cloning and characterization of human estrogen receptor β isoforms
48. Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis
49. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
50. A comparison of transcriptional activation by ER alpha and ER beta
51. Prognostic significance of estrogen receptors in 405 primary breast cancers: A comparison of immunohistochemical and biochemical methods
52. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients
53. Coexpression of estrogen receptor α and β: Poor prognostic factors in human breast cancer
54. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
55. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
56. Partial hormone resistance in mice with disruption of the steroid receptor co-activator-1 (SRC-1) gene
57. Estrogen receptor residues required for stereospecific ligand recognition and activation
58. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
59. Mechanism of resistance to antiestrogens and their implications for crossresistance
60. Cooperative estrogen receptor interaction with concensus or variant estrogen response elements in vitro
61. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers
62. Molecular portraits of human breast tumours
63. Systematic variation in gene expression patterns in human cancer cell lines
64. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells
65. The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer
66. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications
67. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182, 780
68. MCF7/LCC9: An antiestrogen resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early crossresistance to the non-steroidal antiestrogen tamoxifen
69. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells
70. Numatrin expression increases as breast cancer cells progress to estrogen independence and antiestrogen resistance
71. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity
72. Relief of YY1-induced transcriptional repression by protein-protein interaction with the nucleolar phosphoprotein B23
73. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation
74. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes
75. Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase
76. Nuclear substrates of protein kinase C
77. The major phosphorylation site of nucleophosmin (B23) is phosphorylated by a nuclear kinase II
78. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies
79. Autoantibodies to numatrin: An early predictor for relapse in breast cancer
80. Two separate mechanisms for ligand-independent activation of the estrogen receptor
81. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells
82. Regulatory cascades involving calmodulin-dependent protein kinases
83. Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells
84. Calmodulin-stimulated phorphorylation of 17β-estradiol receptor on tyrosine
85. Calmodulin is essential for estrogen receptor interaction with its motif and activation of responsive promoter
86. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells
87. Drug toxicity mechanisms in human hepatoma HepG2 cells: Cyclosporin A and tamoxifen
88. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
89. Differential regulation of AP1 activity by retinoic acid in hormone-dependent and -independent breast cancer cells
90. The quinone reductase gene: A unique estrogen receptor-regulated gene that is activated by antiestrogens
91. Repression of gene expression by oxidative stress
92. Production of 8-hydroxy-2′-deoxyguanosine in DNA by microsomal activation of tamoxifen and 4-hydroxytamoxifen
93. DNA cleavage and 8-hydroxydeoxyguanosine formation caused by tamoxifen derivatives in vitro
94. Peroxidase-catalyzed pro- versus antioxidant effects of 4-hydroxytamoxifen: Enzyme specificity and biochemical sequelae
95. High throughput gene expression profiles associated with antiestrogen responsive vs. resistant breast cancer cells
96. The role of jun, fos and the AP-1 complex in cell-proliferation and transformation
97. Redox cycling by transcription factors NF-kB and AP-1 in lymphocytes
98. Redox regulation of AP-1. A link between transcription factor signaling and DNA repair
99. Joints in the regulatory lattice: Composite regulation by steroid receptor-AP1 complexes
100. Nuclear receptor/AP-1 interaction
101. Endocrine response and resistance in breast cancer: A role for the transcription factor Fos
102. Biological and clinical associations of c-jun activation in human breast cancer
103. 2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
104. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells
105. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells
106. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen
107. Analysis of insulin-like growth factor-I gene expression in malignancy: Evidence for a paracrine role in human breast cancer
108. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients
109. The effects of a constitutive production of TGF-α on the growth of MCF-7 human breast cancer cells in vitro and in vivo
110. Epidermal growth factor in NMU-induced mammary tumors in rats
111. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
112. Altered MAP kinase (ERK1, 2) regualtion in primary cultures of mammary tumor cells: Elevated basal activity and sustained response to EGF
113. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells
114. Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor
115. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens
116. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
117. The effect of tamoxifen on the multidrug resistant phenotype in human breast cancer cells: Isobologram, drug accumulation and gp-170 binding studies
118. Multidrug resistance in breast cancer: A meta analysis of MDR1/gp170 expression and its possible functional significance
119. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells
120. Resistance to tamoxifen with persisting sensitivity to estrogen: Possible mediation by excessive antiestrogen binding site activity
121. Covalent binding of 17β-estradiol and retinoic acid to proteins in the human breast cancer cell line MCF-7
122. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake
123. Steroid sequestration and tightly bound oestrogen-protein complexes in human breast tumors and a breast cancer cell line
124. The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue
125. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma
126. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro
127. Human breast cancer in athymic nude mice: Cytostatic effects of long-term antiestrogen therapy
128. Investigation of the mechanism of tamoxifen stimulated breast tumor growth; non-isomerizable analogues of tamoxifen and its metabolites
129. Human breast cancer cell line xenografts as models of breast cancer: The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines
130. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta
131. Future use of aromatase inhibitors in breast cancer